Summit Therapeutics Inc. Summit Therapeutics Inc.

Summit Therapeutics Inc.

SMMT

Clasificación en acciones #1684
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Precio por acción
$15.60
Capitalización bursátil
$12.44B
Cambio (1 día)
-1.45%
Cambio (1 año)
-18.58%
País
US
Comercio Summit Therapeutics Inc. (SMMT)

Categoría

Healthcare
Historial del precio de la acción de Summit Therapeutics Inc. (SMMT)
Precio más alto de cierre: $16.33 el 2026-10-01

Precio más bajo de cierre: $11.32 el 2015-03-01
Historial del precio de la acción de Summit Therapeutics Inc. desde 2015 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) -6.38%
2025 -2.36%
2024 648.94%
2023 -27.28%
2022 -16.52%
2021 -23.50%
2020 244.19%
2019 23.13%
2018 -88.74%
2017 19.67%
2016 -15.67%
2015 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$533.96 25.21%
US
$232.80 767.04%
US
$137.83 -3.78%
AU
$882.27 8.36%
NL
$290.30 1.99%
BE